Novartis’s Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting
$3bn More In Sales Projected
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a pivotal breast cancer trial earlier than expected, with success in the intermediate risk group representing a $4bn opportunity untapped by rival Eli Lilly.
